1. scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints.
- Author
-
Watson, R S, Broome, T A, Levings, P P, Rice, B L, Kay, J D, Smith, A D, Gouze, E, Gouze, J-N, Dacanay, E A, Hauswirth, W W, Nickerson, D M, Dark, M J, Colahan, P T, and Ghivizzani, S C
- Subjects
GENETIC transformation ,INTERLEUKIN-1 receptors ,CHEMICAL inhibitors ,GREEN fluorescent protein ,ADENO-associated virus ,ARTICULAR cartilage - Abstract
With the long-term goal of developing a gene-based treatment for osteoarthritis (OA), we performed studies to evaluate the equine joint as a model for adeno-associated virus (AAV)-mediated gene transfer to large, weight-bearing human joints. A self-complementary AAV2 vector containing the coding regions for human interleukin-1-receptor antagonist (hIL-1Ra) or green fluorescent protein was packaged in AAV capsid serotypes 1, 2, 5, 8 and 9. Following infection of human and equine synovial fibroblasts in culture, we found that both were only receptive to transduction with AAV1, 2 and 5. For these serotypes, however, transgene expression from the equine cells was consistently at least 10-fold higher. Analyses of AAV surface receptor molecules and intracellular trafficking of vector genomes implicate enhanced viral uptake by the equine cells. Following delivery of 1 × 10
11 vector genomes of serotypes 2, 5 and 8 into the forelimb joints of the horse, all three enabled hIL-1Ra expression at biologically relevant levels and effectively transduced the same cell types, primarily synovial fibroblasts and, to a lesser degree, chondrocytes in articular cartilage. These results provide optimism that AAV vectors can be effectively adapted for gene delivery to large human joints affected by OA. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF